U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479212) titled 'Headache Prevalence and Phenotype in MOG Antibody-Associated Disease' on March 13.

Brief Summary: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease is an inflammatory demyelinating disorder of the central nervous system characterized by antibodies targeting myelin oligodendrocyte glycoprotein. Although the disease most commonly presents with optic neuritis, myelitis, or acute disseminated encephalomyelitis, headache has increasingly been reported as a potentially relevant and disabling symptom. However, the prevalence and clinical characteristics of headache in MOGAD remain poorly defined.

The purpose of this monocen...